iRhythm Expects Revenue of $870M to $880M in 2026
For full year 2026, expect revenue of approximately $870 million to $880 million, or approximately 17% to 18% year-over-year growth, and anticipate adjusted EBITDA margin of approximately 11.5% to 12.5%. "2025 has been a transformative year for iRhythm, with strong execution against our aspiration to drive best-in-class quality systems, record commercial volumes, over 25% year-over-year revenue growth, and achieving free cash flow positivity for the first time in company history," said Quentin Blackford, iRhythm's President and CEO. "Our comprehensive clinical evidence program - including AVALON and CAMELOT publications - continues to reinforce Zio LTCM's clinical superiority in support of addressable market expansion across additional populations and care settings. As we enter 2026, we're well-positioned to accelerate our leadership with multiple growth catalysts ahead, including deepening penetration in primary care and population health through AI-powered risk stratification partnerships, momentum within mobile cardiac telemetry, expansion into adjacent markets such as obstructive sleep apnea, and continued international execution. With our proven ability to scale efficiently, we're confident we can deliver sustainable, profitable growth while transforming cardiac care for millions of patients worldwide."
Trade with 70% Backtested Accuracy
Analyst Views on IRTC
About IRTC
About the author
Investigation into iRhythm Technologies' Corporate Governance Breaches
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of iRhythm Technologies, Inc. breached their fiduciary duties, potentially impacting corporate governance.
- Legal Relief Options: Long-term shareholders of iRhythm stock may seek corporate governance reforms, fund recovery, or court-approved financial awards, aimed at enhancing transparency and accountability within the company.
- Importance of Participation: Shareholder involvement can improve company policies and oversight mechanisms, thereby increasing shareholder value and enhancing the effectiveness and transparency of management.
- Law Firm Background: Halper Sadeh LLC represents investors globally, focusing on securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors.
iRhythm Technologies Executives Accused of Breaching Fiduciary Duties
- Legal Investigation Launched: Kuehn Law, PLLC is investigating whether executives at iRhythm Technologies, Inc. breached their fiduciary duties to shareholders, as a federal securities lawsuit alleges that executives failed to disclose the true purpose of the Zio AT monitor, potentially harming shareholder interests.
- Market Misleading Actions: Insiders repeatedly touted the Zio AT as an innovative product with growth potential, yet failed to clarify that it was intended for high-risk patients, leading investors to misunderstand its premium pricing and artificially inflate the stock price.
- Shareholder Rights Affected: Due to these misleading actions, iRhythm's stock traded at artificially inflated prices during relevant periods, putting shareholders at risk of investment losses, prompting Kuehn Law to urge shareholders to contact them promptly to protect their rights.
- No Legal Fees: Kuehn Law states that all case costs will be covered by the firm, with no fees charged to investors, encouraging shareholders to get involved to ensure the integrity and fairness of the financial markets.
